Cell cycle kinases as therapeutic _targets for cancer
- PMID: 19568282
- DOI: 10.1038/nrd2907
Cell cycle kinases as therapeutic _targets for cancer
Abstract
Several families of protein kinases orchestrate the complex events that drive the cell cycle, and their activity is frequently deregulated in hyperproliferative cancer cells. Although several molecules that inhibit cell cycle kinases have been developed and clinically screened as potential anticancer agents, none of these has been approved for commercial use and an effective strategy to specifically control malignant cell proliferation has yet to be established. However, recent genetic and biochemical studies have provided information about the requirement for certain cell cycle kinases by specific tumours and specialized tissue types. Here, we discuss the potential and limitations of established cell cycle kinases as _targets in anticancer drug discovery as well as novel strategies for the design of new agents.
Similar articles
-
[The serine/threonine kinases that control cell cycle progression as therapeutic _targets].Bull Cancer. 2011 Nov;98(11):1335-45. doi: 10.1684/bdc.2011.1467. Bull Cancer. 2011. PMID: 22020767 Review. French.
-
Therapeutic opportunities to control tumor cell cycles.Clin Transl Oncol. 2006 Jun;8(6):399-408. doi: 10.1007/s12094-006-0193-7. Clin Transl Oncol. 2006. PMID: 16790392 Review.
-
Tubulin-associated drug _targets: Aurora kinases, Polo-like kinases, and others.Semin Oncol. 2006 Aug;33(4):436-48. doi: 10.1053/j.seminoncol.2006.04.007. Semin Oncol. 2006. PMID: 16890798 Review.
-
[Novel anti-cancer compounds _targeting the cell cycle].Nihon Yakurigaku Zasshi. 2009 Jan;133(1):27-31. doi: 10.1254/fpj.133.27. Nihon Yakurigaku Zasshi. 2009. PMID: 19145048 Review. Japanese. No abstract available.
-
Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors.Molecules. 2021 Aug 26;26(17):5170. doi: 10.3390/molecules26175170. Molecules. 2021. PMID: 34500603 Free PMC article. Review.
Cited by
-
An integrative and comparative study of pan-cancer transcriptomes reveals distinct cancer common and specific signatures.Sci Rep. 2016 Sep 16;6:33398. doi: 10.1038/srep33398. Sci Rep. 2016. PMID: 27633916 Free PMC article.
-
Virtual Screening for Potential Allosteric Inhibitors of Cyclin-Dependent Kinase 2 from Traditional Chinese Medicine.Molecules. 2016 Sep 21;21(9):1259. doi: 10.3390/molecules21091259. Molecules. 2016. PMID: 27657032 Free PMC article.
-
High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction.PLoS One. 2015 Feb 11;10(2):e0117523. doi: 10.1371/journal.pone.0117523. eCollection 2015. PLoS One. 2015. PMID: 25671541 Free PMC article.
-
Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers.J Med Chem. 2023 Dec 14;66(23):15629-15647. doi: 10.1021/acs.jmedchem.3c01233. Epub 2023 Nov 15. J Med Chem. 2023. PMID: 37967851 Free PMC article.
-
Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer.Onco_target. 2017 Feb 28;8(9):14794-14805. doi: 10.18632/onco_target.11605. Onco_target. 2017. PMID: 27582547 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources